Thus, we presumed that in BCL9-mutated or amplified recurrent HCC (around 50% of recurrent tumor), combining targeting BCL9 and immune-checkpoint therapies may act as a novel therapeutic approach. This evidence concerns the gene BCL9 and neoplasm.